CryoPort (CYRX) Projected to Post Earnings on Thursday

CryoPort (NASDAQ:CYRX) will likely be announcing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.23) per share and revenue of $41.2170 million for the quarter. CryoPort has set its FY 2025 guidance at EPS.Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 5:00 PM ET.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.09). CryoPort had a net margin of 37.21% and a negative return on equity of 9.79%. The company had revenue of $45.45 million during the quarter, compared to the consensus estimate of $41.74 million. On average, analysts expect CryoPort to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CryoPort Price Performance

Shares of CryoPort stock opened at $9.24 on Thursday. CryoPort has a fifty-two week low of $4.58 and a fifty-two week high of $11.44. The company has a market cap of $462.65 million, a PE ratio of 6.95 and a beta of 1.61. The company has a debt-to-equity ratio of 0.39, a current ratio of 16.24 and a quick ratio of 15.47. The firm has a fifty day moving average price of $9.52 and a two-hundred day moving average price of $7.81.

Insider Transactions at CryoPort

In related news, Director Robert J. Hariri sold 25,000 shares of the stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $9.71, for a total transaction of $242,750.00. Following the completion of the sale, the director owned 51,275 shares in the company, valued at $497,880.25. This trade represents a 32.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Robert Stefanovich sold 9,300 shares of the stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $8.67, for a total transaction of $80,631.00. Following the sale, the chief financial officer owned 207,213 shares of the company’s stock, valued at $1,796,536.71. This trade represents a 4.30% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 39,300 shares of company stock valued at $366,381 in the last quarter. 10.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On CryoPort

A number of hedge funds have recently added to or reduced their stakes in the stock. State of Wyoming grew its holdings in CryoPort by 30.2% during the 2nd quarter. State of Wyoming now owns 14,218 shares of the company’s stock worth $106,000 after acquiring an additional 3,301 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in CryoPort by 300.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock worth $44,000 after acquiring an additional 4,375 shares during the last quarter. Bank of America Corp DE grew its holdings in CryoPort by 20.2% during the 2nd quarter. Bank of America Corp DE now owns 397,421 shares of the company’s stock worth $2,965,000 after acquiring an additional 66,677 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in CryoPort by 9.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,178 shares of the company’s stock worth $136,000 after acquiring an additional 1,557 shares during the last quarter. Finally, Federated Hermes Inc. grew its holdings in CryoPort by 233.2% during the 2nd quarter. Federated Hermes Inc. now owns 84,937 shares of the company’s stock worth $634,000 after acquiring an additional 59,446 shares during the last quarter. Institutional investors own 92.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on CYRX shares. Leerink Partners upgraded shares of CryoPort from a “market perform” rating to an “outperform” rating and set a $16.00 price objective for the company in a research note on Wednesday, August 6th. Weiss Ratings restated a “sell (d+)” rating on shares of CryoPort in a research note on Wednesday, October 8th. KeyCorp upgraded shares of CryoPort from a “sector weight” rating to an “overweight” rating and set a $15.00 price objective for the company in a research note on Wednesday, August 6th. Stephens started coverage on shares of CryoPort in a research note on Tuesday, July 22nd. They issued an “overweight” rating and a $13.00 price objective for the company. Finally, BTIG Research increased their price objective on shares of CryoPort from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, CryoPort currently has an average rating of “Moderate Buy” and an average target price of $12.56.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.